News
The FDA has granted accelerated approval to Modeyso (dordaviprone) for the treatment of diffuse midline glioma harboring an ...
US FDA approves Jazz Pharmaceuticals’ Modeyso to treat recurrent H3 K27M-mutant diffuse midline glioma: Dublin Friday, August 8, 2025, 11:00 Hrs [IST] Jazz Pharmaceuticals plc, ...
When Jazz Pharmaceuticals' incoming CEO Renee Gala takes the reins at the drugmaker next week, she'll have a brand-new launch ...
The U.S. FDA granted accelerated approval to Modeyso for the patients with diffuse midline glioma with an H3 K27M mutation ...
Pharmaceutical Technology on MSN22h
FDA gives accelerated approval to Jazz Pharma’s diffuse midline glioma therapy
The US Food and Drug Administration (FDA) has given accelerated approval to Jazz Pharmaceuticals for Modeyso (dordaviprone) ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback